Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.41 |
| ▸ | MAT2A | P31153 | 1/20 | 0.40 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1109740 | 1.00 | ACMSD (0.47) | ACMSDELANETDP1PTGS2SIGMAR1 | |
| SCHEMBL1094677 | 1.00 | ACMSD (0.47) | ACMSDELANETDP1PTGS2SIGMAR1 | |
| SCHEMBL1094678 | 1.00 | ACMSD (0.47) | ACMSDELANETDP1PTGS2SIGMAR1 | |
| SCHEMBL8356129 | 1.00 | ACMSD (0.47) | ACMSDELANETDP1PTGS2SIGMAR1 | |
| SCHEMBL8359816 | 1.00 | ACMSD (0.47) | ACMSDELANETDP1PTGS2SIGMAR1 | |
| SCHEMBL1094676 | 1.00 | ACMSD (0.47) | ACMSDELANETDP1PTGS2SIGMAR1 | |
| SCHEMBL1109745 | 1.00 | ACMSD (0.47) | ACMSDELANETDP1PTGS2SIGMAR1 | |
| SCHEMBL8360447 | 1.00 | ACMSD (0.47) | ACMSDELANETDP1PTGS2SIGMAR1 | |
| SCHEMBL191429 | 0.98 | ACMSD (0.49) | ACMSDELANETDP1PTGS2SIGMAR1 | |
| SCHEMBL8380044 | 0.98 | ACMSD (0.49) | ACMSDELANETDP1PTGS2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4737513-A1 | RUBBER COMPOSITION FOR TIRE, AND TIRE | BRIDGESTONE CORPORATION (JP) | 2026-05-06 | — | — | EP | disclosed |
| EP-4737517-A1 | RUBBER COMPOSITION FOR TIRE, AND TIRE | BRIDGESTONE CORPORATION (JP) | 2026-05-06 | — | — | EP | disclosed |
| EP-4737515-A1 | RUBBER COMPOSITION FOR TIRES, AND TIRE | BRIDGESTONE CORPORATION (JP) | 2026-05-06 | — | — | EP | disclosed |
| EP-4737516-A1 | RUBBER COMPOSITION FOR TIRES, AND TIRE | BRIDGESTONE CORPORATION (JP) | 2026-05-06 | — | — | EP | disclosed |
| US-20250263511-A1 | COPOLYMER FORMED BY RING-OPENING COPOLYMERIZATION OF CYCLOOLEFIN, PRODUCTION METHOD THEREFOR, RUBBER COMPOSITION, AND CROSSLINKED RUBBER OBJECT | ZEON CORPORATION (JP) | 2025-08-21 | — | — | US | disclosed |
| WO-2025100025-A1 | TREAD RUBBER COMPOSITION, TREAD RUBBER, AND TIRE | 株式会社ブリヂストン | 2025-05-15 | — | — | WO | disclosed |
| WO-2025070000-A1 | RUBBER COMPOSITION, CROSSLINKED RUBBER, AND TIRE | 日本ゼオン株式会社 | 2025-04-03 | — | — | WO | disclosed |
| US-20250091969-A1 | CYCLOPENTENE RECOVERY METHOD | ZEON CORPORATION (JP) | 2025-03-20 | — | — | US | disclosed |
| EP-3822317-B1 | RING-OPENING COPOLYMER COMPOSITION | ZEON CORP (JP) | 2025-02-26 | — | — | EP | disclosed |
| EP-4502058-A1 | RUBBER COMPOSITION AND CROSSLINKED RUBBER OBJECT | Zeon Corporation (JP) | 2025-02-05 | — | — | EP | disclosed |
| WO-2008033894-A2 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| EP-1862484-A1 | NORBORNENE ADDITION COPOLYMER AND MOLDINGS | ZEON CORPORATION (JP) | 2007-12-05 | — | — | EP | disclosed |
| WO-2007056500-A2 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| EP-1747182-A2 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTOR | Acadia Pharmaceuticals Inc. (US) | 2007-01-31 | — | — | EP | disclosed |
| US-20060122278-A1 | di-aromatic compounds for treatment and prevention of diseases and disorders related to estrogen receptors; 2-fluoro-1-methoxy-4-(1-phenyl-cyclohexyl)-benzene | ACADIA PHARMACEUTICALS INC. | 2006-06-08 | — | — | US | disclosed |
| US-20050256210-A1 | Compounds with activity at estrogen receptors | ACADIA PHARMACEUTICALS INC. | 2005-11-17 | — | — | US | disclosed |
| WO-2005108337-A2 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTOR | ACADIA PHARMACEUTICALS INC. (US) | 2005-11-17 | — | — | WO | disclosed |
| US-20050065060-A1 | Solvents containing cycloakyl alkyl ethers and process for production of the ethers | ZEON CORPORATION (JP) | 2005-03-24 | — | — | US | disclosed |
| EP-1405840-A1 | SOLVENTS CONTAINING CYCLOALKYL ALKYL ETHERS AND PROCESS FOR PRODUCTION OF THE ETHERS | Zeon Corporation (JP) | 2004-04-07 | — | — | EP | disclosed |
| WO-1998049128-A1 | PROCESS FOR PREPARING A (HETERO)AROMATIC OLEFIN | DSM N.V. (NL) | 1998-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250091969-A1 | CYCLOPENTENE RECOVERY METHOD | CYC1, CYCS, DHPS | ACMSD 807/4885ELANE 927/4885TDP1 809/4885 |
| US-20060122278-A1 | di-aromatic compounds for treatment and prevention of diseases and disorders related to estrogen receptors; 2-fluoro-1-methoxy-4-(1-phenyl-cyclohexyl)-benzene | GPER1, ESR1, ESR2 | ACMSD 1826/4885ELANE 1816/4885TDP1 1590/4885 |
| US-20050256210-A1 | Compounds with activity at estrogen receptors | ESR2, GPER1, ESRRG | ACMSD 4369/4885ELANE 982/4885TDP1 2334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.